IGF-1 DES (Des(1-3)IGF-I)
Also known as: Des(1-3)IGF-I, Des(1-3) IGF-1, truncated IGF-I, IGF-1 des, des-N-(1-3)-IGF-1
Truncated IGF-1 analog / growth factor peptide
What it is
IGF-1 DES is a modified form of the natural growth factor IGF-1 that people use for muscle growth and recovery, believed to act more potently in local tissue. It's also studied in animal models for neuroprotection and gut development. Not approved for human use; prohibited by WADA; sold as a black-market research compound.
The scientific side
Des(1-3)IGF-I is a naturally occurring truncated variant of human IGF-1 formed by post-translational cleavage that removes the N-terminal tripeptide Gly-Pro-Glu (GPE) from position 1–3 of the mature IGF-1 sequence. The absence of glutamate at position 3 markedly reduces its affinity for IGF-binding proteins (IGFBPs), resulting in approximately 10-fold greater potency than full-length IGF-1 at stimulating hypertrophy and proliferation of cultured cells, because more free peptide is available to engage the type 1 IGF receptor (IGF-1R). Like full-length IGF-1, Des(1-3)IGF-I signals through IGF-1R, activating downstream PI3K/Akt and MAPK/ERK pathways to promote cell growth, survival, and differentiation (PMID 10750042, PMID 11145572). Because IGFBPs do not effectively sequester it, its biological activity is less modulated by circulating binding proteins compared to native IGF-1 (PMID 8930132, PMID 9389554, PMID 11145572). In vivo, selective anabolic effects are particularly evident in gut tissues, and it retains mitogenic, pro-survival, and anti-apoptotic properties.
Class: Truncated IGF-1 analog / growth factor peptide
Administration & storage
- Administration
- Intramuscular injection (animal studyrats; PMID: 33587816)In vitro direct addition to cell culture / organ culture medium (PMID: 7779409PMID: 10750042PMID: 8940346PMID: 12573816)
- Storage
- No storage conditions for des(1-3)IGF-I are described in the reviewed literature. Abundant signs of lower quality, including oxidized peptide forms, were found in black market products of IGF-I analogs.
- Cautions
- Never approved for use in humans; available on the black market as a bodybuilding product with documented quality issues including oxidized peptide forms.,Classified as a prohibited substance in sport by WADA; use carries regulatory and legal risk.,Markedly reduced IGFBP affinity means normal circulating IGFBP buffering mechanisms do not modulate its activity, potentially resulting in unpredictable tissue exposure compared to native IGF-1.,Demonstrated potent mitogenic activity in prostate epithelial and BPH stromal cells in preclinical models; potential oncogenic risk has not been evaluated in humans (PMID: 18026134, PMID: 12573816).,No human pharmacokinetic, safety, or dosing data exist in the reviewed literature — all dosing information derives from animal or in vitro studies only.,Sterile technique is essential for any injectable compound to prevent infection; this is a general harm-reduction principle.
Legal & regulatory status
Not approved for human use. Described in reviewed literature as a black market product available for bodybuilding and never approved for use in humans.
Prohibited substance in sport per reviewed literature
Not stated in reviewed literature — requires manual verification
What it's studied for
- Structural and biochemical characterization; natural occurrence In vitro only
- Des(1-3)IGF-I has been isolated from bovine colostrum, human brain, and porcine uterus. It is ~10-fold more potent than IGF-1 at stimulating hypertrophy and proliferation of cultured cells due to greatly reduced IGFBP binding. Selective anabolic effects in gut tissues noted in vivo. PMID 8930132 Ballard FJ et al. Int J Biochem Cell Biol. 1996
- Neuroblast chemotaxis / neuronal migration In vitro only
- Des(1-3)IGF-I stimulated SH-SY5Y human neuroblast chemotaxis in a dose-dependent manner, increasing cell motility by 90% (P<0.0001) relative to controls. Effect was partly blocked by anti-IGF-1R antibody and PI3K inhibitor wortmannin. PMID 10750042 Puglianiello A et al. J Endocrinol. 2000
- Neuroprotection / brain injury Animal studies only
- In an olfactory bulb organ culture injury model, des(1-3)IGF-1 (which has low affinity for IGFBPs) was found to be ineffective at enhancing neuronal survival post-injury, contrasting with IGF-1, supporting a role for IGFBPs in targeting IGF-1 to receptors in the injured brain. PMID 9554468 Werther GA et al. Horm Res. 1998
- IGF-1 is cleaved into des-N-(1-3)-IGF-1 and the GPE tripeptide in the CNS. Des(1-3)IGF-1 itself was referenced as the parent molecule from which GPE is derived; GPE showed neuroprotective effects in hippocampal neurons in vitro. PMID 10094155 Saura J et al. Neuroreport. 1999
- Olfactory bulb neuronal and glial differentiation in vitro In vitro only
- Des(1-3)IGF-I was 3–5 fold more potent than IGF-1 at stimulating 14C amino acid uptake in rat olfactory bulb organ culture, with half-maximal response at ~20 ng/ml versus ~100 ng/ml for IGF-1. It markedly improved neuronal morphology and expression compared to IGF-1. PMID 7779409 Russo VC, Werther GA. Growth Factors. 1994
- Benign prostatic hyperplasia (BPH) cell growth In vitro only
- Des(1-3)IGF-I, as an IGF-1 analog that does not bind IGF-binding proteins, was found to be a potent mitogen for human BPH stromal cells via stimulation of cell growth and inhibition of apoptosis. A non-hypercalcemic vitamin D3 analogue inhibited this mitogenic activity. PMID 12573816 Crescioli C et al. Mol Cell Endocrinol. 2002
- Gastrointestinal growth and maturation in suckling neonates Animal studies only
- Transgenic hypersecretion of des(1-3) human IGF-I in mouse milk (40–200-fold higher than endogenous mouse IGF) had limited effects on GI tract growth in suckling pups. Small intestinal weight, protein, and DNA content were greater at 8 and 16 days; milk-borne des(1-3)IGF-I was not detected in pup plasma. PMID 9915875 Burrin DG et al. J Nutr. 1999
- Mammary gland development and lactation Animal studies only
- Targeted expression of des(1-3)hIGF-I in transgenic mouse mammary gland influenced mammary gland development, IGFBP expression, and resulted in incomplete mammary involution, ductal hypertrophy, and loss of secretory lobules associated with increased collagen deposition. PMID 8536631 Hadsell DL et al. Endocrinology. 1996
- Prostate epithelial IGF-1 signaling and cancer biology Animal studies only
- Transgenic mice specifically expressing human IGF-1(des) in prostate epithelial cells developed hyperplastic lesions in all mice. Well-differentiated lesions did not progress to adenocarcinoma within a year. Crossing to a prostate cancer model delayed progression of organ-confined tumors in young mice; selection agains PMID 18026134 Kaplan-Lefko PJ et al. Oncogene. 2008
- Wound contraction / fibroblast collagen gel contraction In vitro only
- Des(1-3)IGF-I at 10 ng/ml produced 4.5% fibroblast-embedded collagen gel contraction (P<0.01). Unlike combinations of IGF-1 + IGFBP-1, combinations of des(1-3)IGF-I with IGFBP-1 did not promote enhanced gel contraction, consistent with its low IGFBP affinity. PMID 8940346 Lee YR et al. Endocrinology. 1996
- IGF-1R binding and signaling studies (including IGFBP-3 modulation) In vitro only
- 125I-des(1-3)IGF-I was used as a radioligand (due to its weak IGFBP affinity) to demonstrate that IGFBP-3 interacts directly with IGF-1R, reducing receptor affinity for its ligand. IGFBP-3 at 10 nM provoked 90% displacement of 125I-des(1-3)IGF-I from cell surface binding. PMID 9389554 Mohseni-Zadeh S, Binoux M. Endocrinology. 1997
- IGFBP-3 dose-dependently depressed IGF-1R autophosphorylation and tyrosine kinase activity stimulated by des(1-3)IGF-I in MCF-7 breast carcinoma cells. At 2.5 nM IGFBP-3, >50% inhibition of stimulation by 3 nM des(1-3)IGF-I was observed, despite des(1-3)IGF-I having weak IGFBP affinity, suggesting IGFBP-3 acts via a re PMID 11145572 Ricort JM, Binoux M. Endocrinology. 2001
- Anti-doping detection (sport prohibited substance) Animal studies only
- A validated immunopurification + high-resolution mass spectrometry method detected Des(1-3)IGF-I in rat serum up to 24 h after a single intramuscular administration of 100 µg/kg. Oxidized peptide forms were abundant in black market products, indicating lower quality. PMID 33587816 Mongongu C et al. Drug Test Anal. 2021
- IGF-1 measurement assay development (use of des(1-3)IGF-I as radioligand) Human observational
- Des(1-3)IGF-I was used as a radioligand in a radioimmunoassay (triGF-I RIA) for serum IGF-1 measurement; results were highly correlated with IRMA and standard IGF-I RIA (r=0.967). No added diagnostic advantage over standard IGF-I RIA as radioligand was concluded. PMID 8951618 Homayoun P et al. J Clin Lab Anal. 1996
Safety signals
- Black market products of des(1-3)IGF-I contain abundant oxidized (lower-quality) peptide forms, indicating significant purity concerns for non-pharmaceutical sources. PMID 33587816
- Transgenic expression of des(1-3)IGF-I in prostate epithelium caused hyperplastic lesions in 100% of mice; expression was lost in poorly differentiated tumors, suggesting IGF-1-dependent selection pressure in cancer progression. PMID 18026134
- Des(1-3)IGF-I is a potent mitogen and anti-apoptotic agent for human BPH stromal cells, raising a potential concern for prostate tissue growth stimulation. PMID 12573816
- Transgenic mammary overexpression of des(1-3)hIGF-I caused incomplete mammary involution, ductal hypertrophy, and increased collagen deposition in mice. PMID 8536631
- Reduced IGFBP binding compared to native IGF-1 means that normal homeostatic regulation by IGFBPs is bypassed, potentially leading to exaggerated or uncontrolled receptor activation in tissues. PMID 8930132
Contraindications
- Human use: des(1-3)IGF-I has never been approved for use in humans; no established clinical contraindications exist because human trials have not been conducted. PMID 33587816
Protocol
50 mcg subcutaneous injection, once daily. Cycle: 4-6 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intramuscular injection | 100 µg/kg single dose | Single administration; detection evaluated up to 36 h post-injection | animal | Research PMID 33587816 |
| In vitro cell culture | Not precisely stated; IGF-I and des(1-3)IGF-I used in dose-dependent cell migration assay (specific concentrations not extractable from abstract) | 24 h treatment | in_vitro | Research PMID 10750042 |
| In vitro organ culture | 50 ng/ml (des(1-3)IGF-I); half-maximal response at ~20 ng/ml | Not stated | in_vitro | Research PMID 7779409 |
| In vitro cell culture | Not precisely stated (described as potent mitogen for BPH stromal cells) | Not stated | in_vitro | Research PMID 12573816 |
| In vitro cell assay | 10 ng/ml (des(1-3)IGF-I alone); 1 ng/ml (in combination with IGFBP-1) | Initial 12-h incubation period noted as most prominent | in_vitro | Research PMID 8940346 |
| Oral (ingestion via transgenic mouse milk) | Milk-borne des(1-3)hIGF-I was 40–200-fold higher than endogenous mouse IGF in transgenic dams (no specific µg/kg dose stated) | From birth through weaning at 29 days | animal | Research PMID 9915875 |
| subcutaneous injection | 50 mcg | once daily · 4-6 weeks | bodybuilders and physique athletes seeking muscle hypertrophy | [Community] |
| subcutaneous injection | 100 mcg | once daily · 4-6 weeks | intermediate to advanced bodybuilders seeking muscle hypertrophy | [Community] |
| subcutaneous injection | 150 mcg | once daily · 4-6 weeks | advanced bodybuilders / experienced peptide users | [Community] |
| intramuscular injection | 50 mcg | once daily, post-workout · 4-6 weeks | bodybuilders using site-enhancement / localized hypertrophy protocols | [Community] |
| intramuscular injection | 100 mcg | once daily, post-workout · 4-6 weeks | advanced bodybuilders using site-enhancement protocols | [Community] |
| subcutaneous injection | 20-40 mcg | once daily · 8-12 weeks | biohackers and anti-aging users seeking recovery and body recomposition without extreme anabolism | [Community] |
| subcutaneous injection | 100 mcg | twice daily (morning and post-workout) · 4 weeks | advanced bodybuilders running aggressive hypertrophy cycles | [Community] |
| subcutaneous injection | 50 mcg | once daily, post-workout · 6 weeks on, 6 weeks off | bodybuilders and fitness-focused biohackers using cycling protocols | [Community] |
All studies (14)
- PMID 8951618 Human observational
IGF-1 measurement assay development (use of des(1-3)IGF-I as radioligand) - PMID 7779409 In vitro only
Olfactory bulb neuronal and glial differentiation in vitro - PMID 8536631 Animal studies only
Mammary gland development and lactation - PMID 8930132 In vitro only
Structural and biochemical characterization; natural occurrence - PMID 8940346 In vitro only
Wound contraction / fibroblast collagen gel contraction - PMID 9389554 In vitro only
IGF-1R binding and signaling studies (including IGFBP-3 modulation) - PMID 9554468 Animal studies only
Neuroprotection / brain injury - PMID 9915875 Animal studies only
Gastrointestinal growth and maturation in suckling neonates - PMID 10094155 Animal studies only
Neuroprotection / brain injury - PMID 10750042 In vitro only
Neuroblast chemotaxis / neuronal migration - PMID 11145572 In vitro only
IGF-1R binding and signaling studies (including IGFBP-3 modulation) - PMID 12573816 In vitro only
Benign prostatic hyperplasia (BPH) cell growth - PMID 18026134 Animal studies only
Prostate epithelial IGF-1 signaling and cancer biology - PMID 33587816 Animal studies only
Anti-doping detection (sport prohibited substance)
Frequently asked
What is IGF-1 DES and how is it different from regular IGF-1?
Des(1-3)IGF-I is a naturally occurring truncated variant of IGF-1, lacking the N-terminal tripeptide Gly-Pro-Glu. This structural difference greatly reduces its affinity for IGF-binding proteins (IGFBPs), making it approximately 10-fold more potent than IGF-1 at stimulating cell hypertrophy and proliferation in culture because more peptide is freely available to activate the IGF-1 receptor. It has been isolated from bovine colostrum, human brain, and porcine uterus, but has never been approved for use in humans.
What dose of IGF-1 DES should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the only published dosing data are from animal studies. In rats, a single intramuscular dose of 100 µg/kg was used in an anti-doping detection study. In vitro studies used concentrations of 10–50 ng/ml in cell culture (PMID 7779409, PMID 8940346). No human pharmacokinetic or dosing studies exist in the reviewed literature.
Is IGF-1 DES legal to use or buy?
According to the reviewed literature, des(1-3)IGF-I has never been approved for human use and is classified as a prohibited substance in sport. It is described as available on the black market for bodybuilding purposes. Regulatory status outside of sport (e.g., general consumer law) is not stated in the reviewed literature — requires manual verification with local regulatory authorities.
What are the benefits of IGF-1 DES for muscle growth?
No human studies on IGF-1 DES for muscle growth are available in the reviewed literature. Preclinical data show it is ~10-fold more potent than IGF-1 at stimulating cell hypertrophy and proliferation in culture due to reduced IGFBP binding, and selective anabolic effects in gut tissues have been noted in animal models (PMID 8930132, PMID 9915875). Whether these effects translate to skeletal muscle hypertrophy in humans has not been studied. I don't have reliable study data on human muscle-building outcomes. I won't guess — please consult a licensed provider or peer-reviewed literature directly.
What are the risks or side effects of IGF-1 DES?
Based on the reviewed literature: (1) Black market des(1-3)IGF-I products have documented purity issues including oxidized peptide forms. (2) Transgenic overexpression in prostate caused hyperplastic lesions in all treated mice. (3) Overexpression in BPH stromal cells stimulated proliferation and inhibited apoptosis. (4) Mammary overexpression caused incomplete involution, ductal hypertrophy, and excess collagen in mice. No human safety data exist in the reviewed literature.
Can I stack IGF-1 DES with growth hormone or other peptides?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: des(1-3)IGF-I has been studied in isolation in preclinical models (PMID 8930132, PMID 33587816). No studies on combinations of des(1-3)IGF-I with growth hormone or other peptides in humans appear in the reviewed literature.
Where can I buy IGF-1 DES?
I don't recommend vendors or sources. Please consult a licensed provider.
How long after injection can IGF-1 DES be detected in the body?
Based on a rat study using a single intramuscular dose of 100 µg/kg, unchanged des(1-3)IGF-I was detectable in serum up to 24 hours after administration. The authors note that observations in rats may be extrapolated to humans based on matching in vitro blood incubation results, but this has not been confirmed in human subjects. No human pharmacokinetic data exist in the reviewed literature.
Does IGF-1 DES have a role in treating brain injury or neurological disease?
Preclinical and in vitro data suggest des(1-3)IGF-I has effects on neuronal cells: it stimulated neuroblast chemotaxis by ~90% in cell culture and was 3–5-fold more potent than IGF-1 at supporting neuronal differentiation in olfactory bulb culture. However, one olfactory bulb injury model found des(1-3)IGF-I ineffective at enhancing neuronal survival post-injury (contrasting with full-length IGF-1), suggesting IGFBP-mediated targeting may be important in injured tissue. No human studies on des(1-3)IGF-I for neurological conditions exist in the reviewed literature. I don't have reliable study data on clinical neurological applications. Please consult a licensed healthcare provider or peer-reviewed literature directly.
Should I use IGF-1 DES to treat a medical condition?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider.